Please provide your email address to receive an email when new articles are posted on . Recent data show children who received a booster dose of MenACWY-CRM following primary immunization with either ...
Add Yahoo as a preferred source to see more of our stories on Google. The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...
Thirty-four cases involved children ages 1 to 10; 41 patients not vaccinated against measles. Risk of meningococcal disease up in patients with anatomic/functional asplenia. The quadrivalent ...
Reductions in incidence suggest an impact of the MenACWY vaccine program in this age group. According to a review published in Clinical Infectious Diseases, the incidence of meningococcal disease in ...
January 8, 2008 — A new meningitis vaccine may be better able to produce immunity in infants than the current meningococcal tetravalent glycoconjugate vaccine, according to the results of a randomized ...
Pediatr Infect Dis J. 2016;35(1):81-93. MenACWY-CRM was supplied in 2 vials: 1 vial of lyophilized powder containing 10 μg of MenA oligosaccharide conjugated to CRM 197 and a second liquid conjugate ...
More than a year after picking up the shot from GlaxoSmithKline, Pfizer has won a label expansion in Europe for its MenACWY conjugate vaccine Nimenrix. It’s now the only such vaccine available on the ...
This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...
Teenagers from Brighton have helped a landmark study into how giving a meningitis vaccine to 14 to 19-year-olds helps protect people of all ages. More than 24,000 teenagers took part in the Be on the ...
Dublin, March 12, 2021 (GLOBE NEWSWIRE) -- The "Meningococcal Vaccines Disease Coverage Forecast and Market Analysis to 2024" report has been added to ResearchAndMarkets.com's offering. The US ...
Hosted on MSN
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results